Trial12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE Attacks
Trial details
- Registry ID
- NCT02303626
- Phase
- Phase 2, Phase 3
Drug research
BCX4161
Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.
Drug identity checked against registry records
A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.
Included trials
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| 12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE AttacksNCT02303626 | BioCryst Pharmaceuticals | Phase 2, Phase 3 | Completed | 2016-01Actual |
Regulatory dates and decisions
| No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed. |